Bupivacaine
Approved · EMAAlso known as (RS)-bupivacaine, 1-Butyl-2',6'-pipecoloxylidide, DL-Bupivacaine, Exparel+20 more
(RS)-bupivacaine, 1-Butyl-2',6'-pipecoloxylidide, DL-Bupivacaine, Exparel, Marcaine, Marcaine with Epinephrine, Nocita, Posimir, Racemic bupivacaine, Sensorcaine, Sensorcaine with Epinephrine, Vivacaine, Xaracoll, Zynrelef, dl-1-Butyl-2',6'-pipecoloxylidide, (-)-bupivacaine, (±)-bupivacaine, Bupivacain, Bupivacaina, Bupivicaine, bupivakain, 1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide, Bupivacaine Hydrochloride, Bupivacainum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Latest Advances in Regional Anaesthesia.
Approval: Exparel liposomal (EMA)
Bupivacaine for pain reduction after iliac crest bone graft harvest.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Exparel liposomal is indicated: in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain. in adults and children aged 6 years or… Show full indicationShow less
Exparel liposomal is indicated: in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain. in adults and children aged 6 years or older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds.
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Treatment Efficacy of Local Anesthetic/Steroid Mixture Injection for Patients With Odynophonia
Enhanced Recovery After Surgery (ERAS) in Live Donor Kidney Transplant Recipients
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes3
Journals, researchers & institutions
- Gynecologic oncology1
- Medicina (Kaunas, Lithuania)1
- Orthopedics1
- Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery1
- Akusoba I1
- Bible JE1
- Boone K1
- Buggy DJ1
- Carson L1
- Crosby CG1
- Crowe GG1
- Delaney D1
- Cork University Hospital1
- Fresno Heart and Surgical Hospital1
- Masonic Cancer Center Biostatistics and Bioinformatics1
- Mater Misericordiae University Hospital1
- National Orthopaedic Hospital Cappagh/Mater Misericordiae University Hospital1
- School of Medicine1
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.